Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses

American Journal of Clinical Pathology

Volumn 141, Issue 2, 2014, Pages 262-267

  Gosselin, Robert ^a   Hawes, Emily ^b   Moll, Stephan ^c   Adcock, Dorothy ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Esoterix Inc   (United States)

Author keywords

Dabigatran; Dilute thrombin time; Direct thrombin inhibitor; Ecarin chromogenic assay; Ecarin clotting time; Mass spectrophotometry

Indexed keywords

DABIGATRAN ETEXILATE; ECARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; THROMBIN INHIBITOR;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DILUTE THROMBIN TIME; DRUG BLOOD LEVEL; DRUG MONITORING; ECARIN CHROMOGENIC ASSAY; ECARIN CLOTTING TIME; EMBOLISM PREVENTION; HUMAN; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; TANDEM MASS SPECTROMETRY; THROMBIN TIME; BLOOD; BLOOD ANALYSIS; GOOD LABORATORY PRACTICE; LABORATORY; METHODOLOGY; STANDARD;

DABIGATRAN; DILUTE THROMBIN TIME; DIRECT THROMBIN INHIBITOR; ECARIN CHROMOGENIC ASSAY; ECARIN CLOTTING TIME; MASS SPECTROPHOTOMETRY;

BENZIMIDAZOLES; BETA-ALANINE; BLOOD CHEMICAL ANALYSIS; FIBRINOLYTIC AGENTS; HUMANS; LABORATORIES; LABORATORY PROFICIENCY TESTING; MASS SPECTROMETRY;

EID: 84895081596     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPRNUMI4PVSJ7Q     Document Type: Article

References (13)

1. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
2. Dager WE, Gosselin RC, Kitchen S, et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012;46:1627-1636.
3. Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11:1493-1502.
4. Harenberg J, Giese C, Marx S, et al. Determination of dabigatran in human plasma samples. Semin Thromb Hemost. 2012;38:16-22.
5. Stangier J, Fuering M. Using the HEMOCLOT direct thrombin inhibitor assay to determine the plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138-143.
6. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost. 2012;107:985-997.
7. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003;33:173-183.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al; and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
9. Siegel DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013;34:489-498.
10. Baglin T, Hillarp A, Tripodi A, et al. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis [published online January 24, 2013]. J Thromb Haemost. doi:10.1111/jth.12149.
11. Freyburger G, Macouillard G, Labrouche S, et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing hip or total knee replacement. Thromb Res. 2011;127:457-465.
12. Samama MM, Guinet C, Le Flem L, et al. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis. 2013;35:140-146.
13. ECAT Foundation. External Quality Control for Assays and Tests With a Focus on Thrombosis and Haemostasis. Leiden, the Netherlands: ECAT Foundation; 2012. Survey report 2012-2.